SCHEMBL4159501

SCHEMBL4159501

CCOC(=O)c1cc(C2=C(c3cc(Br)ccc3OCc3ccc(F)cc3)CCC2)cnc1C(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 20/20 0.57
CYP2C9 P11712 4/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4146879 0.93 PTGER1 (0.56) PTGER1CYP2C9
SCHEMBL4151827 0.91 PTGER1 (0.57) PTGER1CYP2C9
SCHEMBL4158183 0.91 PTGER1 (0.58) PTGER1CYP2C9
SCHEMBL4170747 0.90 PTGER1 (0.47) PTGER1CYP2C9
SCHEMBL13697177 0.89 PTGER1 (0.64) PTGER1CYP2C9
SCHEMBL4168540 0.89 PTGER1 (0.49) PTGER1CYP2C9
SCHEMBL4150578 0.89 PTGER1 (0.59) PTGER1CYP2C9
SCHEMBL4159139 0.88 PTGER1 (0.50) PTGER1CYP2C9
SCHEMBL4146588 0.84 MAPT (0.41) PTGER1CYP2C9
SCHEMBL4159517 0.84 PTGER1 (0.64) PTGER1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227591-A1 Cyclopentene compounds GLAXO GROUP LIMITED (GB) 2009-09-10 US disclosed
US-20090227591-A1 Cyclopentene compounds GLAXO GROUP LIMITED (GB) 2009-09-10 US disclosed
US-20090227591-A1 Cyclopentene compounds GLAXO GROUP LIMITED (GB) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227591-A1 Cyclopentene compounds C1R, CYP1B1, ADORA2B PTGER1 246/4885CYP2C9 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.